Grace Therapeutics (GRCE) News Today $3.25 -0.05 (-1.52%) As of 08/22/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period GRCE: Looking Ahead to AcceptanceAugust 13, 2025 | finance.yahoo.comGrace Therapeutics Reports Q2 2025 Earnings and Strategic FocusAugust 13, 2025 | msn.comGrace Therapeutics, Inc.: Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business UpdateAugust 12, 2025 | finanznachrichten.deGrace Therapeutics, Inc. Submits NDA to FDA for GTx-104 Treatment of Aneurysmal Subarachnoid Hemorrhage Following Positive Phase 3 Trial ResultsAugust 12, 2025 | quiverquant.comQGrace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business UpdateAugust 12, 2025 | globenewswire.comGRCE: NDA SubmittedJune 26, 2025 | msn.comGrace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104June 25, 2025 | globenewswire.comGrace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update - MorningstarJune 24, 2025 | morningstar.comMGRACE THERAPEUTICS Earnings Preview: Recent $GRCE Insider Trading, Hedge Fund Activity, and More - NasdaqJune 24, 2025 | nasdaq.comGrace Therapeutics, Inc. (NASDAQ:GRCE) Is Expected To Breakeven In The Near FutureJune 24, 2025 | finance.yahoo.comGrace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business UpdateJune 23, 2025 | globenewswire.comGrace Therapeutics to Participate in the 2025 BIO International ConferenceJune 13, 2025 | globenewswire.comGRCE: Progress ReportJune 5, 2025 | msn.comGRCE Grace Therapeutics, Inc.June 1, 2025 | seekingalpha.comThis Grace Therapeutics Insider Increased Their Holding By 12% Last YearMay 25, 2025 | finance.yahoo.comBiotech Stock Ends Week On High Note Following Bullish Coverage InitiationMay 2, 2025 | msn.comGrace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104April 9, 2025 | globenewswire.comGrace Therapeutics files to sell 8.84M shares of common stock for holdersMarch 10, 2025 | markets.businessinsider.comGrace Therapeutics Files Form S-3 for Flexible Securities OfferingMarch 10, 2025 | tipranks.comGrace Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comGRCE: STRIVE-ON Results ReportedFebruary 21, 2025 | finance.yahoo.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | markets.businessinsider.comGrace Therapeutics reports Q3 EPS (36c), consensus (46c)February 13, 2025 | markets.businessinsider.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | globenewswire.comGrace Therapeutics secures $15m for GTx-104 pre-commercial developmentFebruary 11, 2025 | finance.yahoo.comGrace Therapeutics price target raised to $11 from $8 at Craig-HallumFebruary 11, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for Grace Therapeutics (GRCE)February 11, 2025 | markets.businessinsider.comGrace Therapeutics, Inc.: Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAHFebruary 10, 2025 | finanznachrichten.deGrace Therapeutics reports positive Phase 3 trial results for GTx-104February 10, 2025 | msn.comGrace Therapeutics secures up to $30 million financingFebruary 10, 2025 | msn.comGrace Therapeutics announces private placement financing of up to $30MFebruary 10, 2025 | markets.businessinsider.comGrace Therapeutics announces results from Phase 3 STRIVE-ON trialFebruary 10, 2025 | markets.businessinsider.comGrace Therapeutics Announces Private Placement Financing of up to $30 MillionFebruary 10, 2025 | globenewswire.comGrace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAHFebruary 10, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)January 30, 2025 | markets.businessinsider.com3 US Penny Stocks With Market Cap Under $70MJanuary 23, 2025 | finance.yahoo.comGrace Therapeutics Inc Ordinary SharesJanuary 10, 2025 | morningstar.comM Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address GRCE Media Mentions By Week GRCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GRCE News Sentiment▼1.850.66▲Average Medical News Sentiment GRCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GRCE Articles This Week▼21▲GRCE Articles Average Week Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Contineum Therapeutics News Korro Bio News Instil Bio News Rapt Therapeutics News Actuate Therapeutics News Cybin News Journey Medical News biote News MEI Pharma News C4 Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GRCE) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access